Stay updated on Pembrolizumab in Recurrent HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent HNSCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdds the disease topic 'Squamous cell carcinoma of the head and neck' and a Resources section linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0, with no visible changes to study details, eligibility criteria, endpoints, or locations.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.4.2 is now listed, replacing the previous v3.4.1. The site-wide notice about government operating status has been removed.SummaryDifference0.4%

- Check71 days agoChange DetectedA site-wide funding status notice was added, and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check78 days agoChange DetectedThe page adds a glossary display and updates footer/version text (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0), replacing earlier lowercase variants and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Recurrent HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent HNSCC Clinical Trial page.